2011
Should a Sentinel Node Biopsy Be Performed in Patients with High‐Risk Breast Cancer?
Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS. Should a Sentinel Node Biopsy Be Performed in Patients with High‐Risk Breast Cancer? International Journal Of Breast Cancer 2011, 2011: 973245. PMID: 22295240, PMCID: PMC3262582, DOI: 10.4061/2011/973245.Peer-Reviewed Original ResearchAxillary diseaseSLN biopsyHigh riskNegative SLN biopsy resultsHigh-risk breast cancerNegative SLN biopsySLN biopsy resultsLymph node irradiationSentinel node biopsyBreast cancer patientsAxillary irradiationNode irradiationClinical characteristicsNodal biopsyNodal involvementNode biopsyAdditional surgeryBiopsy resultsCancer patientsBreast cancerBiopsyPatientsBayesian nomogramTest characteristicsDisease
2008
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer
Mayer E, Miller K, Rugo H, Peppercorn J, Carey L, Ryabin N, Josephs K, Winer E, Burstein H. A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. Journal Of Clinical Oncology 2008, 26: 519-519. DOI: 10.1200/jco.2008.26.15_suppl.519.Peer-Reviewed Original Research
2007
A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer
Mayer E, Miller K, Rugo H, Peppercorn J, Carey L, Ryabin N, Winer E, Burstein H. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. Journal Of Clinical Oncology 2007, 25: 561-561. DOI: 10.1200/jco.2007.25.18_suppl.561.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerAdjuvant bevacizumabAntiangiogenic therapyAnthracycline-containing neoadjuvant chemotherapyHigh-risk breast cancerAdjuvant antiangiogenic therapyResidual invasive carcinomaSingle-agent bevacizumabCycles of therapyTreatment-related toxicityChemotherapy-resistant diseasePhase II trialResidual breast cancerRisk of recurrenceNovel antiangiogenic therapiesEligible patientsMild arthralgiaAgent bevacizumabBevacizumab monotherapyII trialPrimary endpointMedian ageOngoing trialsOral chemotherapy